Two Sigma Advisers’s Aerie Pharmaceuticals AERI Stock Holding History

Two Sigma Advisers’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-97,900	Closed	-$1.48M	–	2777
2022 Q3	$1.48M	Buy	97,900 +79,600	+435%	+$925K	﹤0.01%	1331
2022 Q2	$137K	Sell	18,300 -13,600	-43%	-$95.9K	﹤0.01%	2352
2022 Q1	$290K	Sell	31,900 -3,300	-9%	-$25.4K	﹤0.01%	2236
2021 Q4	$247K	Sell	35,200 -200,600	-85%	-$2.1M	﹤0.01%	2211
2021 Q3	$2.69M	Sell	235,800 -56,200	-19%	-$822K	0.01%	1089
2021 Q2	$4.67M	Buy	292,000 +170,400	+140%	+$2.92M	0.01%	890
2021 Q1	$2.17M	Buy	+121,600	New	+$2.1M	0.01%	1227
2017 Q2	–	Sell	-19,500	Closed	-$884K	–	2451
2017 Q1	$884K	Buy	+19,500	New	+$870K	﹤0.01%	1647

Two Sigma Advisers's AERI Position: Q4 2022 in Review

Two Sigma Advisers sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 97,900 shares — an estimated $1.48M sold.

Two Sigma Advisers first reported a position in AERI in Q1 2017 and held it in 8 quarters. The position peaked at $4.67M in Q2 2021. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Two Sigma Advisers reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Two Sigma Advisers sold 97,900 Aerie Pharmaceuticals shares in Q4 2022, an estimated $1.48M.
Two Sigma Advisers first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 8 quarters.
Two Sigma Advisers's Aerie Pharmaceuticals position peaked at $4.67M in Q2 2021.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.